Dr. Xuejun (Sherry) Gu got her Ph.D in Biochemical Engineering from Massachusetts Institute of Technology and has been working in the biopharmaceutical field for the past twenty years, including two years at Bristol Myers Squibb and eighteen years at Eli Lilly and Company.  During her time at Lilly, she made significant technical contributions including establishing the mammalian cell culture platform, which enabled multiple Lilly biological product approvals.  She also had several significant leadership roles, including Director of Cell Line & Upstream Development, Director of Downstream Development, Program Team Leader, and AutoImmune Portfolio Leader, which helped her gain a deep understanding of drug development throughout the product lifecycle.